CD8A and type 1 diabetes mellitus: Many studies related to CAR-T therapy against AIDs are focused on Type 1 diabetes (T1D), a T cell-mediated autoimmune disease in which both CD4+ and CD8+ T cells are involved in the destruction of insulin-producing islet β cells.